The Be The Match BioTherapies® board has the experience and perspective to guide and govern us as we work to save more lives through cellular therapy. Our board members have a strong foundation in cellular therapy development, medical practice and clinical research, with many holding leadership roles and faculty positions at their organizations, along with serving on committees for industry organizations.
Sergio Giralt, MD, Chair
Chief Attending, Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
Sergio A. Giralt, MD, is chief of the Adult Bone Marrow Transplant (BMT) Service in the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center and a professor of medicine at Weill Cornell Medical College.
Dr. Giralt’s clinical research has focused on three areas: developing better tolerated conditioning regimens for older or medically infirmed patients with hematological malignancies; developing novel hematopoietic cell transplantation (HCT) therapies (conditioning regimens plus post-transplant therapies) for autologous and allogeneic HCT for myeloma; and pursuing strategies that will significantly reduce HCT symptom burden and toxicities. As BMT Service chief, he has had extensive experience designing, implementing and performing HCT studies, both as a principal investigator and as a collaborator.
Dr. Giralt holds key positions with several organizations, including the International Bone Marrow Transplant Registry Executive Committee, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Steering Committee, the National Marrow Donor Program® (NMDP)/Be The Match® Board of Directors, and the Clinical Advisory Board of the website, Managing Myeloma. He is the past president of the American Society for Blood and Marrow Transplantation (ASBMT) as well as the past chair of the BMT CTN and of the CIBMTR® (Center for International Blood and Marrow Transplant Research®).
He is a member of several professional societies, including the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the ASBMT and the International Society of Hematology.
Dr. Giralt received his Doctor of Medicine degree from Universidad Central de Venezuela and completed his postgraduate internship at the University Hospital of Caracas. He completed an internal medicine residency at Good Samaritan Hospital and a postdoctoral fellowship in hematology and oncology at The University of Texas MD Anderson Cancer Center.
David Porter, MD, Member
Director, Cell Therapy and Transplantation
University of Pennsylvania
David Porter, MD, is the Jodi Fisher-Horowitz professor of Leukemia Care Excellence at the Perelman School of Medicine and Abramson Cancer Center, and director of the Cell Therapy and Transplant program at Penn Medicine.
Dr. Porter is an accomplished clinical investigator with principal research interests in development of novel methods of cellular therapy, HCT and allogeneic adoptive immunotherapy. He worked with colleagues at the University of Pennsylvania to pioneer successful development of CAR T cells to treat B cell cancers like acute lymphocytic leukemia, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Additional research highlights include development of novel trials designed to prevent graft-versus-host disease (GVHD) after allogeneic HCT by blocking lymphocyte trafficking, and studies to enhance graft-vs-tumor activity at the time of transplant, after non-myeloablative therapy, and for relapse after HCT.
Dr. Porter chairs or serves on numerous local, national and international committees focused on hematologic malignancies, HCT and cell therapy. He has been a member of the NMDP Board of Directors since 2013 and current serves as Chair. He is the recipient of several prestigious awards, including recognition for professionalism, mentorship and clinical research. He was the recipient of the Leukemia and Lymphoma Society Service to Mankind Award. He is a member of the American Board of Internal Medicine Hematology Exam Committee and a member of ASH, ASCO and the ASBMT.
Dr. Porter is a graduate of the University of Rochester and earned a Doctor of Medicine degree from Brown University. He completed his internship and residency at Boston University Hospital and his fellowship training at Brigham and Women’s Hospital and Harvard Medical School.
Nelson Chao, MD, Member
Nelson Chao, MD, is professor of medicine and immunology and chief of the Division of Cellular Therapy at Duke University Medical Center. His research revolves around immunology and HCT, with earlier work focusing on antigen presentation and methods to block GVHD.
Dr. Chao’s research also focuses on experimental allogeneic transplantation, specifically understanding and improving HCT for adult patients. The subjects of focus for this research have been cord blood and hematopoiesis, as well as understanding the signals required for self-renewal and engraftment.
Dr. Chao’s clinical studies in HCT, which have changed the treatment paradigm, focus on patient care issues reflecting dedication to improving clinical outcomes for patients.
Recently Dr. Chao has been involved in global cancer efforts, leading the newly created Duke Global Cancer Program, where he, along with other researchers, produced several peer-reviewed publications.
Among numerous additional honors, Dr. Chao was a Harvard University Dreyfus Fellow and received his Bachelor of Arts with honors from Harvard University. He was also a Yale Fellow and received his Doctor of Medicine degree with honors from Yale University. He completed his residency in internal medicine at Stanford Medical Center and interned at Menlo Medical Clinic.
Jeffrey S. Miller, MD, Member
Professor of Medicine, Division of Hematology, Oncology and Transplantation
Deputy Director, Masonic Cancer Center
University of Minnesota
Jeffrey Miller, M.D., is professor of medicine for the division of Hematology, Oncology and Transplantation and the deputy director of the Masonic Cancer Center at the University of Minnesota. Dr. Miller has more than 20 years of experience studying the biology of natural killer cells and other immune effector cells and their use in clinical immunotherapy with more than 170 peer-reviewed publications.
He is a member of numerous societies, including ASH, the American Association of Immunologists and the American Society of Clinical Investigation. Additionally, Dr. Miller serves on the editorial board for Blood and is a reviewer for a number of journals and National Institutes of Health grants. In 2015, he received the National Cancer Institute Outstanding Investigator Award.
Dr. Miller received a Bachelor of Science degree from Northwestern University and received his Doctor of Medicine degree from Northwestern University School of Medicine. He completed his internship and residency in internal medicine at the University of Iowa. He joined the faculty at the University of Minnesota in 1991 after completing a post-doctoral fellowship there in hematology, oncology and transplantation.
David Schubert, MBA, MS, Member
Chief Operating Partner
Accelerator Life Science Partners
David M. Schubert is Chief Operating Partner of Accelerator Life Science Partners (ALSP), a biotechnology-focused venture-capital-backed investment vehicle located in New York City, San Diego and Seattle.
From 2012 to 2014, Schubert served as executive director of the Houston Area Translational Research Consortium (HATRC) at Rice University, a biotechnology-based not-for-profit organization that focused on filling the gap between R&D investment and translation of discovery to the clinic in the form of marketable products to treat diseases. While at HATRC, Schubert was a venture partner at ALSP.
From 2005 to 2012, Schubert served as the president and chief business officer of ALSP. Prior to ALSP, he launched CellExSys Corporation from Targeted Genetics Corporation (where he led Business Development and Investor Relations from 1997 to 2001). He then successfully led the acquisition of CellExSys by Chromos Molecular Systems.
Schubert holds a Master of Business Administration degree with concentrations in marketing and management from Pennsylvania State University and a Master of Science degree in biology with a concentration in immunology from Utah State University. He received a Bachelor of Science degree in biology and a Bachelor of Arts degree in psychology from Eastern Nazarene College.
In addition to serving on the board of directors of the NMDP/Be The Match and Be The Match BioTherapies®, Mr. Schubert serves on the board of directors of Enventure.
Randal (Randy) Mills, PhD, Staff
Chief Executive Officer
NMDP/Be The Match
As CEO of NMDP/Be The Match, Randy Mills, Ph.D., leads an organization of 1,350 professionals and more than 3,000 volunteers, fighting so that every person who needs a life-saving blood stem cell transplant gets the right match, exactly when they need it. With more than 20 years of experience as a leader of biotechnology, Dr. Mills has shown how innovation coupled with rigorous execution can alter the course of disease and prevent human suffering.
Before joining the NMDP/Be The Match, Dr. Mills served as CEO of the California Institute for Regenerative Medicine (CIRM), the state’s $3 billion agency charged with accelerating more than 300 stem cell programs for patients in need. Under his leadership, CIRM 2.0 was launched, creating an organization internationally recognized for its speed, innovation and productivity.
As CEO of Osiris®Therapeutics, Dr. Mills led the company through its IPO and launched several first-in-class cell therapy products, including remestemcel-L—the first stem cell drug used for the treatment of children with deadly GVHD. Dr. Mills was also a co-founder of Regeneration Technologies, Inc., where he invented BioCleanse®, the first sterilization system for human tissue transplantation accepted by the FDA. To date, this technology has safeguarded more than three million transplantations without a single case of disease transmission.
Dr. Mills was named to the World Regenerative Medicine Congress list of the World’s 50 Most Influential People in Regenerative Medicine and named Emerging Pharmaceutical Leader by Pharmaceutical Executive Magazine. He is the recipient of the George W. Hyatt Memorial Award for outstanding scientific contribution to the field of transplant and his BioCleanse technology won the World Economic Forum’s Technology Pioneer award.
Dr. Mills serves on numerous boards, including as past chairman of KeraLink International, a pioneer in the restoration of sight through corneal transplantation. He received his Bachelor of Science in cell science and holds a doctorate degree in drug discovery and development from the University of Florida.
Amy Ronneberg, MBA, Staff
Be The Match BioTherapies
Chief Financial Officer and Chief of Staff
NMDP/Be The Match
Amy Ronneberg, MBA, is the president of Be The Match BioTherapies. She is responsible for developing and delivering a strategic plan to grow and expand our portfolio of product offerings. She is also the chief financial officer and chief of staff for NMDP/Be The Match, and is responsible for planning, implementing and directing the organization’s finances, and collaborating with NMDP/Be The Match executives and Board of Directors to develop and implement strategic business plans to meet the changing health care environment.
Ronneberg joined NMDP/Be The Match in July 2013. She has more than 20 years of experience in financial and operational leadership, most recently as executive vice president, chief financial officer and chief operating officer of North American Membership Group, a private equity-owned media company. Prior to that, she spent 12 years at Capella University, where she served as vice president of Finance and led enterprise-wide operations and customer service.
Ronneberg currently serves on the board for Magenta Therapeutics, Tmunity Therapeutics, the Finance Committee for Allina Health and the Women’s HealthCare Leadership Trust. She earned her Master of Business Administration degree from Capella University and a Bachelor of Business Administration degree in accounting from the University of Wisconsin-Eau Claire.
Steven Devine, MD, Staff
Chief Medical Officer
Be The Match BioTherapies
Chief Medical Officer
NMDP/Be The Match
Associate Scientific Director, CIBMTR® (Center for International Blood and Marrow Transplant Research®)
As the medical director for Be The Match BioTherapies, Steven Devine, MD is responsible for evaluating the science behind cellular therapies and their potential clinical impact. Additionally, he advises the leadership team on determining the best opportunities for leveraging the many assets of our organization to partner with cell and gene therapy companies who are bringing innovative therapies to patients.
Dr. Devine also serves as the senior vice president of research and associate scientific director at the CIBMTR, providing oversight of the CIBMTR Minneapolis research team, defining strategy and setting direction. In addition, he works to identify, evaluate and acquire new business opportunities for the prospective clinical research program.
Prior to joining Be The Match BioTherapies and the CIBMTR, he was Professor of Internal Medicine and Director of the Blood and Marrow Transplant program at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research. Before that, he held positions at Washington University in St. Louis, the University of Illinois in Chicago and Emory University in Atlanta.
He has also served on the graft-versus-host advisory boards of Bristol Myers Squibb, Incyte Pharmaceuticals, Kiadis Inc., and Genzyme. He is a past member of the boards of directors of the National Cancer Institute (NCI) Alliance for Clinical Trials cooperative group and the ASBMT. He is past chair of the National Heart Lung and Blood/NCI-sponsored BMT CTN Steering Committee, and of the Transplant Committee for the Alliance, part of the NCI’s National Clinical Trials Network.
Dr. Devine is a member of ASH, ASCO, the Association for the Advancement of Cancer Research and ASBMT. He graduated from the University of Massachusetts Medical School and trained in hematology and oncology at the University of Chicago and Emory University.